Ioanna Cheronis

*This is an algorithmically generated author record based on publicly available information.

Research Interests

Ioanna Cheronis has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

Amy Jackson-Fisher
10Translational Oncology, Pfizer Inc., San Diego, California
20 shared publications
Anthony W. Tolcher
NEXT Oncology, San Antonio, Texas
20 shared publications
Cathy Cen Guo
Pfizer Inc. San Diego California USA
20 shared publications
David S. Hong
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
20 shared publications
Edmund J. Keliher
13Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts
20 shared publications
Jeanne Tie
Peter MacCallum Cancer Centre, Melbourne, Australia
20 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Table 4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Descriptive summary of serum PF-07062119 PK parameters (with 400 μg priming dose) for cycle 1.
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table 4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Descriptive summary of serum PF-07062119 PK parameters (with 400 μg priming dose) for cycle 1.
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Summary of CD3+, CD8+, CD8+/GZMB+, PD-L1+. Immune cell fold changes in C3D1 biopsies from baseline (screening) biopsies
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Summary of CD3+, CD8+, CD8+/GZMB+, PD-L1+. Immune cell fold changes in C3D1 biopsies from baseline (screening) biopsies
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
PET imaging visualization of CD8+ tracer retention in tumor lesions BOT
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S6 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
PET imaging visualization of CD8+ tracer retention in tumor lesions BOT
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Table 5 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Descriptive summary of serum PF-07062119 PK parameters (without priming dose) for cycle 1.
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table 5 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Descriptive summary of serum PF-07062119 PK parameters (without priming dose) for cycle 1.
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Table 3 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Summary of best overall response, objective response (confirmed), PFS, and DOR based on investigator assessment (RECIST v1.1) in all patients (full analysis set).
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table 3 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Summary of best overall response, objective response (confirmed), PFS, and DOR based on investigator assessment (RECIST v1.1) in all patients (full analysis set).
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Summary of incidence of DLTs, TEAEs, and treatment-related TEAEs in patients who received at least one dose of PF-07062119 (safety analysis set).
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Table 2 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Summary of incidence of DLTs, TEAEs, and treatment-related TEAEs in patients who received at least one dose of PF-07062119 (safety analysis set).
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Results from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Results of serum cytokine responses
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Results from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Results of serum cytokine responses
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Treatment-related TEAEs (in >15% patients) by preferred term and maximum CTCAE grade in patients who received at least one dose of PF-07062119
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S3 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Treatment-related TEAEs (in >15% patients) by preferred term and maximum CTCAE grade in patients who received at least one dose of PF-07062119
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Patient disposition flow diagram
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S1 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Patient disposition flow diagram
Open Access
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Representativeness of study participants with advanced gastrointestinal cancers
Website
Google Scholar
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S1 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
by Marwan Fakih, Toshihiko Doi, Anthony Tolcher, David Hong, Jeanne Tie, Wells Messersmith, Takafumi Koyama, Lee Rosen, Joana Borlido, Michael A. Damore, et al.
Representativeness of study participants with advanced gastrointestinal cancers

Show all